Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients

Research output: Contribution to journalArticle

Abstract

Objective: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. Design: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. Study sample: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation. Results: Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. Conclusions: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalInternational Journal of Audiology
DOIs
StateAccepted/In press - Jul 20 2017

Fingerprint

Head and Neck Neoplasms
Hearing Loss
cancer
Cisplatin
incidence
Drug Therapy
counseling
PubMed
Head and Neck Cancer
Hearing Impairment
Cancer Patients
Counseling
Cohort Studies
Prospective Studies
Radiation
Incidence
literature

ASJC Scopus subject areas

  • Language and Linguistics
  • Linguistics and Language
  • Speech and Hearing

Cite this

@article{d00750b3b8c349bba7842c6a987b3177,
title = "Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients",
abstract = "Objective: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. Design: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. Study sample: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation. Results: Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. Conclusions: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.",
author = "Nicole Schmitt and Brandi Page",
year = "2017",
month = "7",
day = "20",
doi = "10.1080/14992027.2017.1353710",
language = "English (US)",
pages = "1--6",
journal = "International Journal of Audiology",
issn = "1499-2027",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients

AU - Schmitt, Nicole

AU - Page, Brandi

PY - 2017/7/20

Y1 - 2017/7/20

N2 - Objective: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. Design: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. Study sample: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation. Results: Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. Conclusions: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.

AB - Objective: Review of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation. Design: Studies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. Study sample: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation. Results: Studies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens. Conclusions: Newer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=85025480950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025480950&partnerID=8YFLogxK

U2 - 10.1080/14992027.2017.1353710

DO - 10.1080/14992027.2017.1353710

M3 - Article

SP - 1

EP - 6

JO - International Journal of Audiology

JF - International Journal of Audiology

SN - 1499-2027

ER -